市场调查报告书
商品编码
1271794
临床试验市场 - 按阶段、研究设计、治疗领域和预测,2023-2032 年Clinical Trials Market - By Phases, By Study Design, By Therapeutic Area & Forecast, 2023 - 2032 |
由于亚太地区临床试验数量的增加,预计到 2032 年全球临床试验市场规模将达到高估值。
不断增加的慢性病负担增加了该地区对临床试验的需求。 据世界卫生组织称,印度估计有 2500 万人处于糖尿病前期。
行业产品创新的加剧,进一步促进了市场的扩大。 例如,2022 年 10 月,领先的临床研究机构 ICON plc 宣布,它已被美国生物医学高级研究与开发机构选中,对一种炭疽疫苗进行临床试验。
整个临床试验行业根据阶段、研究设计、治疗领域和地理区域进行细分。
根据阶段,I 期临床试验市场份额预计到 2032 年将显着增长。 I 期临床试验结果为进一步的药物开发提供了背景。 这些试验着眼于副作用、安全性、患者的适当剂量等。 此外,由于研究方法的最新进展,I 期临床试验的高效性对该领域的增长做出了积极贡献。
根据研究设计,观察性研究的市场规模将在 2022 年达到 110 亿美元以上。 与干预措施和扩大可及性相比,观察性研究具有更高的成本效益,这将有利于扩大该领域。 这些研究是快速的,并为研究人员提供了对现实世界中正在发生的事情的洞察力。 此外,它在调查罕见结果和不常见副作用方面的作用将推动其在未来十年的采用。
按治疗领域划分,到 2032 年,肿瘤临床试验市场销售额预计将显着增长。 癌症患者的增加以及随之而来的政府对癌症研究投资的增加有利于该行业的发展。 例如,2023 年 1 月,加拿大政府宣布加拿大卫生研究院 (CIHR) 投资超过 2300 万美元,成立加拿大儿童癌症研究联盟。 此类研发计划的增加将增加未来几年对临床试验的需求。
到 2032 年,欧洲临床试验行业的价值预计将超过 230 亿美元。 临床研究数量的增加和政府对临床研究的支持将有助于该地区的扩张。 事实上,该地区有许多提供高质量临床研究的协会,例如欧洲 CRO 联合会 (EUCROF)。 此外,慢性病患病率的上升进一步增加了该地区对临床研究的需求。
Global Clinical Trials Market size is anticipated to record an appreciable valuation by 2032, owing to the increasing prospects for performing clinical trials in the Asia Pacific. The consistent rise in the burden of chronic disorders has accentuated the need for clinical trials in the region. As per the WHO, an estimated 25 million people are prediabetic in India.
Escalating product innovations in the industry are further contributing to market expansion. For instance, in October 2022, ICON plc, a leading clinical research organization announced its selection by US Biomedical Advanced Research and Development Authority for conducting an anthrax vaccine clinical trial.
The overall clinical trials industry is segmented in terms of phases, study design, therapeutic area, and region.
Based on phases, the clinical trials market share from the phase I segment is expected to grow considerably through 2032. Phase I clinical trial results serve as the background for further progress in drug development. These studies examine the side effects, safety, and appropriate dosage level for patients. Furthermore, high efficacy of phase I clinical trials due to recent advancements in research methodologies is positively contributing to segment growth.
Based on the study design, the market size from the observational study segment recorded more than USD 11 billion in 2022. The cost-effectiveness of observational studies over their interventional and expanded access counterparts will favor segment expansion. These studies are quick and provide researchers with insights into what occurs in real-life situations. Moreover, their usefulness in investigating rare outcomes and unusual side effects will boost their adoption in the next ten years.
In terms of therapeutic area, the clinical trials market revenue from the oncology segment is poised to depict significant growth through 2032. Increasing incidences of cancer and the subsequent rise in investments by the government in cancer research are working in favor of segment growth. To illustrate, in January 2023, the government of Canada announced an investment of more than USD 23 million from the Canadian Institutes of Health Research (CIHR) for the establishment of the Canadian Pediatric Cancer Consortium for pediatric cancer research. Increasing R&D initiatives such as these will augment the demand for clinical trials in the forthcoming years.
Europe clinical trials industry is expected to be valued at over USD 23 billion by 2032. Rising number of clinical studies, along with favorable government support for clinical research, may contribute to regional expansion. In fact, the region is also home to many associations, such as the European CRO Federation (EUCROF), that provide high-quality clinical research. Moreover, the growing prevalence of chronic diseases has further increased the need for clinical research in the region.